Therapy Detail

Therapy Name PX-866
Synonym
Therapy Description

Oncothyreon (PX-866) is a PI3K inhibitor, which inhibits the activation of the PI3K/Akt signaling pathway, thereby inhibiting cancer cell motility and growth (PMID: 17766839).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
PX-866 Oncothyreon PI3K Inhibitor (Pan) 34 Oncothyreon (PX-866) is a PI3K inhibitor, which inhibits the activation of the PI3K/Akt signaling pathway, thereby inhibiting cancer cell motility and growth (PMID: 17766839).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS G12D lung adenocarcinoma sensitive PX-866 Preclinical Actionable In a preclinical study, the treatment of KRAS G12D mutant mouse lung cancer with PX-866, a PI3K inhibitor, resulted in inhibition of tumor growth (PMID: 18493606). 18493606
Clinical Trial Phase Therapies Title Recruitment Status